Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Unconventional wisdom: A controversial income pick
Rigid definitions of income and growth shares may be holding investors back.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
Why ASX miners will handily beat banks in the long-term
After a stellar run for banks, investors are wondering whether they can continue their outperformance or if a rotation into miners is imminent. There’s a good case that a switch is coming, and it may last decades, not just years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,780.30 | 4.80 | -0.05% |
| CAC 40 | 7,973.03 | 34.59 | -0.43% |
| DAX 40 | 21,787.00 | 115.42 | -0.53% |
| Dow JONES (US) | 44,332.61 | 415.02 | -0.93% |
| FTSE 100 | 8,700.53 | 26.75 | -0.31% |
| HKSE | 21,133.54 | 241.92 | 1.16% |
| NASDAQ | 19,516.16 | 275.83 | -1.39% |
| Nikkei 225 | 38,787.02 | 279.51 | -0.72% |
| NZX 50 Index | 12,902.19 | 57.60 | 0.45% |
| S&P 500 | 6,028.72 | 54.85 | -0.90% |
| S&P/ASX 200 | 8,511.40 | 9.30 | -0.11% |
| SSE Composite Index | 3,303.67 | 33.01 | 1.01% |